^
    over2years
    Interesting study ⁦@JAMAOnc⁩➡️ Cetuximab Rechallenge ➕Avelumab in Pretreated #Patients è RAS Wild-type Metastatic #Colorectal #Cancer è baseline ctDNA for #KRAS , NRAS, BRAF, and EGFR-S492R mutation: mOS 11.6 mos & mPFS 3.6 mos. ⁦@OncoAlert⁩ https://t.co/sJsaswS8WB (@SalemGIOncDoc)
    Clinical • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    EGFR mutation • BRAF mutation • EGFR S492R
    |
    Erbitux (cetuximab) • Bavencio (avelumab)